Abstract: Pediatric rheumatic diseases (PRD) encompass an heterogeneous group
of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile
systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and
others. The PRD constitute a small market which is of little interest for
pharmaceutical industries. Difficulties in operating in this specific area
relate to problems which are peculiar to children, such as specific methods for
the assessment of the primary outcome, or paediatric formulations, with the
need of setting large networks in order to collect in a reasonable time frame
an adequate number of patients.